US Patent

US8501723 — Pharmaceutical compositions comprising fesoterodine

Formulation · Assigned to UCB Pharma GmbH · Expires 2027-06-07 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical granulate containing fesoterodine or a salt/solvate thereof, combined with a stabilizer such as xylitol or sorbitol.

USPTO Abstract

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Drugs covered by this patent

Patent Metadata

Patent number
US8501723
Jurisdiction
US
Classification
Formulation
Expires
2027-06-07
Drug substance claim
No
Drug product claim
Yes
Assignee
UCB Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.